NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. Fundamental Analysis
NovaBay Pharmaceuticals, Inc. (NBY) shows weak financial fundamentals with a PE ratio of 1.14, profit margin of 1.15%, and ROE of 1.09%. The company generates $0.1B in annual revenue with weak year-over-year growth of -6.45%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze NBY's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNBY demonstrates superior asset utilization.
Valuation Score
ExcellentNBY trades at attractive valuation levels.
Growth Score
ModerateNBY shows steady but slowing expansion.
Financial Health Score
ExcellentNBY maintains a strong and stable balance sheet.
Profitability Score
WeakNBY struggles to sustain strong margins.
Key Financial Metrics
Is NBY Expensive or Cheap?
P/E Ratio
NBY trades at 1.14 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NBY's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values NovaBay Pharmaceuticals, Inc. at 2.26 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -10.71 times EBITDA. This is generally considered low.
How Well Does NBY Make Money?
Net Profit Margin
For every $100 in sales, NovaBay Pharmaceuticals, Inc. keeps $1.15 as profit after all expenses.
Operating Margin
Core operations generate -2.73 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.09 in profit for every $100 of shareholder equity.
ROA
NovaBay Pharmaceuticals, Inc. generates $93.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
NovaBay Pharmaceuticals, Inc. generates limited operating cash flow of $-153.78M, signaling weaker underlying cash strength.
Free Cash Flow
NovaBay Pharmaceuticals, Inc. generates weak or negative free cash flow of $-153.78M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.19 in free cash annually.
FCF Yield
NBY converts -8.82% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1.14
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.007
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.26
vs 25 benchmark
P/S Ratio
Price to sales ratio
28.78
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.59
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.001
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.09
vs 25 benchmark
ROA
Return on assets percentage
0.93
vs 25 benchmark
ROCE
Return on capital employed
-3.79
vs 25 benchmark
How NBY Stacks Against Its Sector Peers
| Metric | NBY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1.14 | 29.43 | Better (Cheaper) |
| ROE | 108.85% | 800.00% | Weak |
| Net Margin | 114.59% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.59 | 0.30 | Weak (High Leverage) |
| Current Ratio | 2.00 | 4.64 | Strong Liquidity |
| ROA | 93.00% | -17936.00% (disorted) | Strong |
NBY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews NovaBay Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-99.29%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
99.67%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
99.69%
Industry Style: Defensive, Growth, Innovation
High Growth